Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: On Friday, Xenetic Biosciences Q4 GAAP EPS $(0.77) Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate

Author: Benzinga Newsdesk | March 25, 2024 06:59am
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.

Posted In: XBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist